Research - As we theorized early this month, Tekmira Pharmaceuticals (TKMR) is changing its name and re prioritizing drug development efforts around Hepatitis B. Unfortunately, our musings that investors may reward the … Continue Reading
Read nowResearch - This is the first clinical step for “new Tekmira”. Announced last week, Tekmira is merging with OnCore Biopharma to focus on therapeutics for Hepatitis B.
Read nowResearch - Tekmira Pharmaceuticals (TKMR) is merging with privately held OnCore Biopharma, which develops drugs targeting the Hepatitis B virus (HBV).
PremiumInsights - Tekmira Pharmaceuticals (TKMR) and European drug developer Bavarian Nordic (BAVA.CO) are receiving significant attention in early trading on Wednesday morning with announcements that their two … Continue Reading
Read nowInsights - Tekmira (TKMR) revealed the first data for TKM-HBV publicly on Wednesday at a medical conference. Though early, Mr. Fink likes what he sees.
Read nowInsights - Ebola stocks are still in vogue, though for new reasons on Thursday. The DailyMail reported on Wednesday evening that up to four drug companies, including Shire … Continue Reading
Read nowInsights - In which we suggest taking profit and/or selling Calls on TKMR equity position. A handy return from $11.50 in July.
Read now
